Abstract Transforming growth factor (TGF) b1 may be a candidate for a serologic tumor marker. In this study, the plasma levels of TGF-b1 in patients with brain tumors were measured using enzyme-linked immunosorbent assay before and after tumor removal. Patients were divided into four groups, the control group and the benign, malignant, and metastatic brain tumor groups. All brain tumor groups showed significant increases in the levels of TGF-b1 before tumor removal (6.36 AE 3.94, 17.0 AE 9.7, and 12.2 AE 10.3 ng/ml for the benign, malignant, and metastatic groups, respectively). When compared with the results obtained in the control group (1.12 AE 0.74 ng/ml), significant decreases in TGF-b1 concentrations after total tumor removal were found in both the benign and malignant brain tumor groups (2.55 AE 2.00 and 8.93 AE 5.73 ng/ml, respectively; p Z 0.0001 and p Z 0.003, respectively). On the other hand, plasma TGF-b1 levels in the metastatic brain tumor group showed a slight but significant increase (14.7 AE 9.3 ng/ml, p Z 0.035) after tumor removal. In a case of lowgrade astrocytoma, plasma levels of TGF-b1 were found to be 3.6 and 1.1 ng/ml before and after tumor removal, respectively. However, recurrent tumor was noted in this patient 7 months later, and the levels of TGF-b1 were 26.2 and 8.4 ng/ml before and after the second * Corresponding author. 901, Chung Hwa Road, Yung Kang City, Tainan, Taiwan.
Introduction
Transforming growth factor beta (TGF-b) is a family of multifunctional cytokines that regulate cell proliferation, differentiation, and extracellular matrix production [1, 2] . Deregulation of the expression or signaling of TGF-b has been implicated in the pathogenesis of a variety of diseases, including cancer [3] and fibrosis [4] . Under physiologic conditions, TGF-b inhibits the proliferation of normal astrocytes but it loses its growth-inhibitory potential toward gliomas due to alterations in the expression of cell cycle inhibitors. Lines of evidence suggest that TGF-b is actively secreted by tumor cells in the late stages of cancer development, and it contributes to cell growth, invasion, metastasis as well as to the decrease in host-tumor immune responses [1] . There are three distinct TGF-b isoforms (namely, TGF-b1, TGF-b2, and TGF-b3) and their effects depend on the type, differentiation state, and physiologic conditions of the target cells [3] . Among the TGF-b isoforms, TGF-b1 is the most abundant and most universally expressed compared with the other two [4, 5] . Because of these properties, TGF-b1 has been the focus of most of the preclinical and clinical studies.
A recent report demonstrated that elevated serum level of TGF-b1 was a more sensitive indicator of small hepatocellular carcinomas than alpha-fetoprotein, which suggests that measuring serum TGF-b1 levels may be clinically useful for the diagnosis of others tumors as well [6] . Furthermore, based on preclinical studies that showed the production of TGF-b1 by tumors, we hypothesized that the TGF-b1 level should decrease after the surgical removal of the tumors. Thus, we compared the plasma levels of TGF-b1 in patients with brain tumors before and after tumor removal and evaluated the potential of using this measurement as a new tool for the diagnosis and monitoring of malignancy in brain tumors.
Patients and methods
The study protocol was approved by the ethics review committee of the Medical Faculty of the Kaohsiung Medical University Hospital in Kaohsiung, Taiwan. All patients and controls gave their written informed consent. From September 2004 to December 2006, 68 patients were included in this study. Among them, 17 had benign brain tumors (13 with meningiomas, two with low-grade astrocytoma, and one each with pituitary adenoma and neurilemmoma), 14 had malignant brain tumors (six with glioblastoma multiforme, three each with anaplastic astrocytoma and malignant meningioma, and two with gliosarcoma), 24 had metastatic brain tumors (15 with lung carcinomas, three with melanoma, and one each with breast carcinoma, colon carcinoma, hepatoma, cervical carcinoma, neuroblastoma, and malignant thymoma) and 13 were controls (all received cranioplasty for skull bone defect). Blood samples (10 ml) were collected in tubes containing 10 mg of ethylenediaminetetraacetic acid and 0.15 ml of aprotinin from patients before and 7 days after surgery. The samples were centrifuged at 2000 Â g for 10 minutes, and the supernatants were carefully aspirated and stored at e20 C until analysis. The plasma TGF-b1 level was measured with enzyme-linked immunosorbent assay (ELISA) kits (Biosource International, Carlsbad, California USA) of antibody sandwich format as described previously [7] . The first antibody used to coat the plates (capture antibody) is a monoclonal antibody 4A11, which was used as the detection antibody. Streptavidin-conjugated horseradish peroxidase (HRP) was used as the secondary antibody; H 2 O 2 mixed with tetramethylbenzidine was the substrate. The 96-well microtiter plates were applied to an automatic plate reader to measure the absorbance at 450 nm using 540 nm as a wavelength correction. The TGF-b1 level was assayed by comparing the peroxidase activity in wells containing known amounts of purified TGF-b1 with the activity in the wells containing the plasma of the patient. The known amounts of purified TGF-b1 were used as a standard for ELISA. Samples were run in triplicate. Each assay was repeated to ensure the absorbance values Table 1 The plasma levels of transforming growth factor b1 before and after tumor removal in benign brain tumor. were within the range of the detectable standard cure.
Since the procedure could not distinguish between the active and latent forms of TGFb1, the measured TGFb1 level was referred to as the total TGFb1. Comparison between various groups was conducted using Wilcoxon signed rank test, and a p value of less than 0.05 was considered to be statistically significant.
Results
The clinical data and plasma levels of TGF-b1 of benign brain tumor, malignant brain tumor, and metastatic brain tumor are shown in Tables 1 to 3 respectively.
The plasma levels of TGF-b1 in patients before and after tumor removal are shown in Table 4 . Prior to surgery, plasma TGF-b1 levels in the benign (6.36 AE 3.94 ng/ml, mean AE SEM), malignant (17.0 AE 9.7 ng/ml), and metastatic (12.2 AE 10.3 ng/ml) brain tumor groups were significantly higher than the control (1.1 AE 0.7 ng/ml). Significant decreases in TGF-b1 levels were found in benign (2.55 AE 2.00 ng/ml; p Z 0.0001) and malignant (8.93 AE 5.73 ng/ml; p Z 0.003) brain tumor groups after tumor removal. However, a slight but significant increase in plasma TGF-b1 levels was seen in the metastatic brain tumor group (14.7 AE 9.3 ng/ml; p Z 0.035) after surgery (Table 4) . Brain magnetic resonance images of a case of low-grade astrocytoma are shown in Fig. 1 (top panel) . Grossly, total removal of this low-grade astrocytoma was performed in this patient (Figs. 1A and 1B, top panel) . Plasma TGF-b1 levels of this patient before and after tumor removal were 3.6 and 1.1 ng/ml, respectively (Fig. 1, bottom panel) . The patient had a recurrent tumor 7 months later (Fig. 1C, top  panel) . A second operation was performed ( Fig. 1D; top   panel) , and the pathologic report revealed glioblastoma multiforme. The TGF-b1 concentrations of this patient before and after the second surgery were 26.2 and 8.4 ng/ ml, respectively ( Fig. 1; bottom panel) .
Discussion
Malignant tumors secrete into the circulation a number of proteins and peptides such as human chorionic gonadotropin, carcinoembryonic antigen, and alpha-fetoprotein, Figure 1 . Brain magnetic resonance images (MRI) and plasma TGF-b1 levels of a patient with Grade II astrocytoma before and after tumor removal. Top panel: MRI of the right temporo-pariental lobe before (A) and after (B) a grossly total tumor removal was performed. Tumor recurred seven months later in this patient, and images were taken before (C) and after (D) a second operation. Bottom panel: corresponding plasma TGF-b1 levels for the same patient. which can be used as helpful markers for the diagnosis, therapy, and prognosis of cancers. Likewise, TGF-b1 has recently emerged as such a marker for brain tumors [8e10] .
In the present study, we measured plasma TGF-b1 levels in patients with brain tumors before and after tumor removal. Our data showed that the plasma TGF-b1 levels in patients with brain tumor before surgical management were significantly higher than those of healthy controls, suggesting that TGF-b1 was indeed produced by brain tumors. Furthermore, significant decreases in plasma TGFb1 were found after tumor removal in both the benign and malignant brain tumor groups. These results are consistent with our hypothesis that surgical removal of the brain tumors can reduce the production of TGF-b1.
On the other hand, there was a slight but significant increase in plasma TGF-b1 levels in patients with metastatic brain tumor despite a significant tumor reduction by surgery. The results indicate that a quantity of unknown tumor cell clones may still reside outside the circumscribed tumor that has been removed surgically. These residual tumors together with another main tumor that were not removed were likely to be responsible for the production of TGF-b1 after surgery. Such an increase in TGF-b1 levels in the metastatic brain tumor group may also reflect the less favorable outcome in these patients.
In a murine malignant glioma model, high-grade human brain tumors have been shown to produce higher levels of TGF-b1 than those from low-grade brain tumors and from normal brain tissue [11e14] . When different histologic subgroups of gliomas were examined, TGF-b1 production was found to increase with anaplastic grade [15] . Furthermore, TGF-b1 production was significantly higher in glioblastomas than in the slow-growing glioma. In the present study we have also shown that plasma TGF-b1 levels in patients with malignant tumors are significantly higher than those with benign tumors before tumor removal (Table 4) . The results imply that the malignant brain tumors synthesize higher amounts of TGF-b1 than benign tumors. Consequently, malignant brain tumors can induce more severe immunosuppression, and immunosuppression in a tumor-bearing host is a major obstacle in cancer treatment. TGF-b1 can down-regulate monocyte surface marker expression, cytokine secretion, cytotoxicity, and T-cell responsiveness, all of which paralyze the immune system of the host, thus contributing to the growth and progression of tumors [16e21] .
In addition, immunosuppression may also lead to the development of tumor metastases in cancer patients. It has been widely accepted that the tumor-induced immunosuppression is associated with tumor burden. However, an important question remains as to whether immunosuppression could be reversed if the tumor burden is lessened. Previous studies have revealed that antitumor immune function could recover partially following reduction of tumor burden via primary tumor resection [22e25] . In other words, tumor-induced immunosuppression could be partially reversed by tumor resection in cancer patients. Our results reveal that the plasma levels of TGF-b1 decrease after brain tumor removal, which may lead to the possible lessening or relieving of host immune suppression.
In conclusion, the present study showed that plasma TGF-b1 levels in the benign and malignant brain tumor groups were elevated and that surgical removal of the tumors reduced the production of this cytokine. These results suggest that plasma TGF-b1 may be used as a marker for the diagnosis and monitoring of tumor malignancy. Further investigations are warranted to determine whether these findings contribute to morbidity and mortality or therapeutic outcome.
